




Autonomic Dysfunction in Multiple System Atrophy




Mitchell Miglis, MD

Clinical Associate Professor


Neurology and Sleep Medicine

Stanford Autonomic Disorders Program

Hemodynamic Changes During Orthostasis



Baroreflex



Cardiovascular Manifestations: Orthostatic Hypotension

A sustained fall of at least 20 mm Hg in SBP or 10 mm Hg in DBP within 3 minutes of standing or upright tilt

—AAS/AAN definition (2011)

Orthostatic Hypotension

- Many causes of OH, including severe heart failure, adrenal insufficiency, dehydration, and severe anemia
 - Prevalence is high
 - Increases with age
 - Overall prevalence of OH in patients > 65 years is about 20%


Orthostatic Hypotension

- It is a sign (not a symptom)
- Symptoms alone are not required nor sufficient to diagnose OH
- BP measurements in the supine and standing positions are required to diagnose OH
- Can be symptomatic or asymptomatic

Symptomatic Orthostatic Hypotension

- Typical well-known symptoms include:
 - Dizziness, lightheadedness, feeling about to faint when standing
 - Loss of consciousness (syncope)
 - Visual changes
- Less well-known symptoms include:
 - Coat-hanger pain
 - Shortness of breath
 - Angina
 - Cognitive slowing
 - Fatigue

Symptomatic Orthostatic Hypotension



MCA = middle cerebral artery
Vm = velocity

Two Types of Orthostatic Hypotension




Non-Neurogenic Orthostatic Hypotension

- Very common in population > 65 years old
- Causes:
 - Anemia of unknown origin
 - Volume depletion
 - Heart failure
 - Significant varicose veins
 - Adrenal insufficiency
- Medications can cause or aggravate it
 - Diuretics
 - Antihypertensives
 - Nitrates
 - Sildenafil and others
 - Tricyclic antidepressants


Neurogenic Orthostatic Hypotension

- Disorder of noradrenergic neurotransmission resulting in deficient norepinephrine release from postganglionic sympathetic nerves
- Orphan condition affecting < 200,000 people in the United States
 - An estimated 75-80% of patients with MSA have nOH
 - nOH can be an early feature of MSA



When to Suspect Orthostatic Hypotension


- Unexplained syncope/fall
- Typical symptoms (dizziness, lightheadedness, fatigue, confusion, gait disorders, neck pain, vision disturbance when standing)
- Patients on vasodilators, diuretics, alpha- and beta-blockers, tricyclic antidepressants
- Anyone with MSA



Management of Neurogenic Orthostatic Hypotension

Neurogenic Orthostatic Hypotension: Principles of Treatment

- Goal of treatment is to improve symptoms and quality of life—not to normalize BP
- Asymptomatic OH does not require pharmacologic treatment




Nonpharmacologic Treatment


- Elevating the head of the bed 30-45 degrees with an electric bed/mattress
- Compression garments (binders/stockings)
- Increased fluid and salt intake:
 - Approximately 2 L of water daily
 - Patients with nOH who rapidly consume 500 mL of water can raise SBP by 30 mm Hg within 10-15 minutes
 - Liquids other than water do not provide the same BP response
 - It is recommended that nOH patients add 1-2 teaspoons of salt per day to their diet
- Physical conditioning
 - Lower-body strength training, moderate nonstrenuous activities
 - Stationary recumbent bicycle, rowing machine, water-based activities
 - Avoid upright exercises, treadmill, or running

Changes in systolic
after patients with


BP), and heart rate (HR)
failure (bottom) drank




Ambulatory 24-Hour BP Monitoring




Elevating the Head of the Bed Is the Most Effective Treatment



Dynamic Physical Exercise Lowers BP in Patients With Neurogenic Orthostatic Hypotension




Exercise in a Swimming Pool Prevents the Fall in BP




ρ = density of the fluid
 g = acceleration of gravity

h = height of the column of fluid above the layer where pressure is being measured


Physical Counter-Maneuvers to Prevent Orthostatic Hypotension



Breaking the Vicious Cycle of Orthostatic Hypotension



Pharmacology of Neurogenic Orthostatic Hypotension




AAAD = aromatic amino acid decarboxylase ACh = acetylcholine AChE = acetylcholinesterase

CNS = central nervous system

NET = norepinephrine transporter


Midodrine

- FDA approval: 1996
- Selective alpha-1-adrenergic agonist
- Does not cross blood-brain barrier
- Predictable pressor effect ~1 hour post-administration
- Duration of action: ~3 hours
- Dosage: 2.5-10 mg up to 3 times/day
- Side effects:
 - Supine hypertension
 - Piloomotor reactions (goosebumps)
 - Urinary retention (rare)



Droxidopa

- FDA approval: 2014
 - First drug for nOH approved in 20 years
- Synthetic precursor of NE
- Predictable peak plasma concentration and pressor effect ~1 hour post-administration
- Duration of action: 4-6 hours
- Dosage: 100-600 mg 3 times/day




Fludrocortisone

- Evidence-based data on fludrocortisone for nOH treatment are limited
- Increases renal sodium reabsorption, intravascular volume, and BP
- No more than 0.1-0.2 mg/day
- Long acting: clinical effects take 3-5 days to be noticeable (biological half-life is 36 hours)
- Side effects:
 - Hypokalemia and arrhythmia (short term)
 - Edema (short term)
 - Left ventricular hypertrophy and heart and renal failure (long term)
 - Increases risk of all-cause hospitalization in patients with OH

Pyridostigmine

- Acetylcholinesterase inhibitor
- Little effect as isolated drug
- Appears to enhance effect of other medications to increase sympathetic nerve activity in response to orthostatic stress
- Side effects: abdominal cramps, diarrhea, sialorrhea, excessive sweating, and urinary incontinence

Pharmacology of Neurogenic Orthostatic Hypotension



AAAD = aromatic amino acid decarboxylase ACh = acetylcholine AChE = acetylcholinesterase

CNS = central nervous system

NET = norepinephrine transporter

Clinical Management of Supine Hypertension in Patients With Neurogenic Orthostatic Hypotension

- Supine hypertension with droxidopa (> 160 mm Hg)
 - ~10% of patients
 - More common in those with higher baseline supine BP
 - Initial clinical management includes clinic and home BP monitoring with nonpharmacologic interventions (elevation of head of bed)
- Avoid dosing within 4 hours prior to bedtime
 - Physicians and patients should monitor supine BP as medications are up-titrated
 - Short-acting antihypertensive agents can be administered at bedtime if necessary

Urogenital Manifestions

- ❖ Lower urinary tract symptoms are the sole initial manifestation of MSA in 18% of patients, with a mean onset of 2.8 years prior to the onset of motor symptoms
- ❖ Urinary storage symptoms:
 - ❖ **Overactive bladder symptoms** (urinary urgency, daytime frequency, nocturia, and urge incontinence)
 - ❖ **Voiding symptoms** (hesitancy, intermittent urinary stream or poor flow, sensation of incomplete bladder emptying, double voiding)
- ❖ Voiding difficulties with incomplete bladder emptying are the most frequently reported urinary symptoms in MSA
- ❖ Among reported urinary symptoms; Voiding difficulty seen in 79%, nocturnal urinary frequency in 74%, urinary urgency in 63%, nocturnal enuresis in 19% ; and urinary retention in 8%.
- ❖ Urinary urgency and increased frequency are common in the early disease stages. While urinary retention are more common in the late disease stages
- ❖ Cutoff at >100 mL PVR volume is set to secure high specificity of clinically established diagnosis. A lower PVR is allowed for clinically probable diagnosis
- ❖ Erectile dysfunction can be a presenting symptoms in ~37-48 % of patients with MSA
- ❖ Erectile dysfunction occurred in up to 97% of men with definite multiple system atrophy

Overactive Bladder Treatments

- *Behavior Modification/Pelvic Floor Therapy*
- • Fluid management
 - Avoid excessive urine production
 - Appropriate intake/timing of fluids
 - Treat sleep apnea
 - Avoid bladder irritants: caffeine, alcohol, spicy foods, citrus, processed sugars, milk
- Manage constipation
- Pelvic floor therapy
 - Kegels
 - Physical therapy: biofeedback and electrical stimulation
- Bladder retraining
 - Timed urination (prompted)
 - Delayed urination


Overactive Bladder Treatments

- Medications: Oxybutynin, Myrbetriq)
- Some cause more side effects
 - Dry mouth
 - Constipation
 - Blurred vision
 - Potential for cognitive problems (e.g. memory); especially oral Oxybutynin
- *Procedural Management*
- Nerve stimulation (technically not approved for neurogenic bladder)
 - Tibial aka PTNS
 - Sacral aka InterStim
- Botulinum toxin injection into bladder (Botox)


Gastrointestinal Manifestations

- Gut motility commonly affected in MSA
- Can result in slowed upper GI motility (gastroparesis): early satiety, bloating with meals, post-prandial nausea, as well as slowed lower GI motility (constipation)
- Pelvic floor dyssergia common- paradoxical contraction of sphincter and pelvic floor muscles

Sweating Dysfunction/ Temperature Intolerance




REM Sleep Behavior Disorder





Stridor





Thank you!



Stanford MSA Center of Excellence

